Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 26, Issue 3, Pages 447-454Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2007.13.0690
Keywords
-
Categories
Funding
- NCI NIH HHS [CA 33399, CA34233, CA122105, CA109335] Funding Source: Medline
Ask authors/readers for more resources
Purpose The heterogeneity of diffuse large B-cell lymphoma (DLBCL) has prompted the search for new markers that can accurately separate prognostic risk groups. We previously showed in a multivariate model that LMO2 mRNA was a strong predictor of superior outcome in DLBCL patients. Here, we tested the prognostic impact of LMO2 protein expression in DLBCL patients treated with anthracycline-based chemotherapy with or without rituximab. Patients and Methods DLBCL patients treated with anthracycline-based chemotherapy alone ( 263 patients) or with the addition of rituximab ( 80 patients) were studied using immunohistochemistry for LMO2 on tissue microarrays of original biopsies. Staining results were correlated with outcome. Results In anthracycline-treated patients, LMO2 protein expression was significantly correlated with improved overall survival ( OS) and progression-free survival (PFS) in univariate analyses ( OS, P =.018; PFS, P =.010) and was a significant predictor independent of the clinical International Prognostic Index (IPI) in multivariate analysis. Similarly, in patients treated with the combination of anthracycline-containing regimens and rituximab, LMO2 protein expression was also significantly correlated with improved OS and PFS ( OS, P =.005; PFS, P =.009) and was a significant predictor independent of the IPI in multivariate analysis. Conclusion We conclude that LMO2 protein expression is a prognostic marker in DLBCL patients treated with anthracycline-based regimens alone or in combination with rituximab. After further validation, immunohistologic analysis of LMO2 protein expression may become a practical assay for newly diagnosed DLBCL patients to optimize their clinical management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available